Truist on DexCom (DXCM): 'Catalyst Rich 27-28 Ahead'

May 15, 2026 8:31 AM

Truist Securities analyst Richard Newitter reiterated a Buy rating and $80.00 price target on DexCom (NASDAQ: DXCM).The analyst commented: "LRP ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found